{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:27:56Z","timestamp":1789021676829,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,2,9]],"date-time":"2013-02-09T00:00:00Z","timestamp":1360368000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00213-013-3007-y","type":"journal-article","created":{"date-parts":[[2013,2,9]],"date-time":"2013-02-09T02:40:28Z","timestamp":1360377628000},"page":"623-625","source":"Crossref","is-referenced-by-count":13,"title":["Elevated clozapine serum levels in combination with perazine"],"prefix":"10.1007","volume":"226","author":[{"given":"M.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Unterecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Deckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pfuhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,9]]},"reference":[{"key":"3007_CR1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","volume":"37","author":"P Baumann","year":"2004","unstructured":"Baumann P, Hiemke C, Ulrich S et al (2004) The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37:243\u2013265","journal-title":"Pharmacopsychiatry"},{"key":"3007_CR2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-39980","volume":"36","author":"A Frick","year":"2003","unstructured":"Frick A, Kopitz J, Bergemann N (2003) Omeprazole reduces clozapine plasma concentrations. A case report. Pharmacopsychiatry 36:121\u2013123","journal-title":"Pharmacopsychiatry"},{"key":"3007_CR3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00115-008-2471-9","volume":"79","author":"E Haen","year":"2008","unstructured":"Haen E, Greiner C, Bader W, Wittmann M (2008) Expanding therapeutic reference ranges using dose-related reference ranges. Nervenarzt 79:558\u2013566","journal-title":"Nervenarzt"},{"key":"3007_CR4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-199408000-00011","volume":"14","author":"C Hiemke","year":"1994","unstructured":"Hiemke C, Weigmann H, H\u00e4rtter S, Dahmen N, Wetzel H, M\u00fcller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14:279\u2013281","journal-title":"J Clin Psychopharmacol"},{"key":"3007_CR5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"C Hiemke","year":"2011","unstructured":"Hiemke C, Baumann P, Bergemann N et al (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195\u2013235","journal-title":"Pharmacopsychiatry"},{"key":"3007_CR6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","volume":"29","author":"E Jaquenoud Sirot","year":"2009","unstructured":"Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, Ansermot N, Baumann P, Eap CB (2009) ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 29:319\u2013326","journal-title":"J Clin Psychopharmacol"},{"key":"3007_CR7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","volume":"16","author":"M Jerling","year":"1994","unstructured":"Jerling M, Lindstr\u00f6m L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368\u2013374","journal-title":"Ther Drug Monit"},{"key":"3007_CR8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00004714-200112000-00005","volume":"21","author":"JM Meyer","year":"2001","unstructured":"Meyer JM (2001) Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 21:569\u2013574","journal-title":"J Clin Psychopharmacol"},{"key":"3007_CR9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JCP.0b013e3181acd20b","volume":"29","author":"B Pfuhlmann","year":"2009","unstructured":"Pfuhlmann B, Hiemke C, Unterecker S, Burger R, Schmidtke A, Riederer P, Deckert J, Jabs B (2009) Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol 29:392\u2013394","journal-title":"J Clin Psychopharmacol"},{"key":"3007_CR10","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.pnpbp.2009.04.006","volume":"33","author":"G Schaller","year":"2009","unstructured":"Schaller G, Jacobi A, Rotter A, Kornhuber J, Hillemacher T (2009) Perazine elevates clozapine serum levels by inhibiting hepatic metabolism. Prog Neuropsychopharmacol Biol Psychiatry 33:908\u2013909","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3007_CR11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s002130000489","volume":"151","author":"E St\u00f6rmer","year":"2000","unstructured":"St\u00f6rmer E, Brockm\u00f6ller J, Roots I, Schmider J (2000) Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl) 151:312\u2013320","journal-title":"Psychopharmacology (Berl)"},{"key":"3007_CR12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1734-1140(09)70141-0","volume":"61","author":"J W\u00f3jcikowski","year":"2009","unstructured":"W\u00f3jcikowski J, Daniel WA (2009) Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism\u2014an in vitro study. Pharmacol Rep 61:851\u2013858","journal-title":"Pharmacol Rep"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-013-3007-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-013-3007-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-013-3007-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T20:12:45Z","timestamp":1558642365000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-013-3007-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,9]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["3007"],"URL":"https:\/\/doi.org\/10.1007\/s00213-013-3007-y","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,9]]}}}